公开(公告)号：US10215766B2

公开(公告)日：2019-02-26

申请号：US14969698

申请日：2015-12-15

Applicant: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY ,  SYSMEX CORPORATION

Inventor： Midori Shima ,  Keiji Nogami ,  Yuka Tabuchi ,  Hiroshi Kurono

IPC: G01N33/86 ,  G01N33/49 ,  G01N21/49 ,  G01N21/75 ,  G01N21/82

Abstract: Disclosed is a blood sample determination method including: emitting light to a measurement specimen prepared by mixing a clotting time measuring reagent and a blood sample suspected to be derived from a subject having lupus anticoagulant or a coagulation factor inhibitor, to obtain optical information about an amount of light from the measurement specimen; obtaining at least one parameter regarding derivative of clot waveform, based on the obtained optical information; and determining, based on a value of the obtained parameter, whether the blood sample is suspected to be a sample derived from a subject having lupus anticoagulant or is suspected to be a sample derived from a subject having a coagulation factor inhibitor.

公开(公告)号：US20180011114A1

公开(公告)日：2018-01-11

申请号：US15512187

申请日：2015-09-24

Applicant: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Keiji Nogami ,  Midori Shima ,  Tetsuhiro Soeda ,  Takehisa Kitazawa

IPC: G01N33/86 ,  C07K16/36

CPC classification number: G01N33/86 ,  C07K16/36 ,  C07K2317/31 ,  G01N2333/755 ,  G01N2333/96444 ,  G01N2333/9645 ,  G01N2800/224 ,  G01N2800/52 ,  G01N2800/56

Abstract: The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered that in APTT-based one-stage clotting assay, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately, and also that in APTT-based Bethesda assay, FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately.

公开(公告)号：US20220326262A1

公开(公告)日：2022-10-13

申请号：US17606274

申请日：2020-04-23

Applicant: SEKISUI MEDICAL CO., LTD. ,  PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY

Inventor： Toshiki KAWABE ,  Yukio ODA ,  Mari EMMI ,  Midori SHIMA ,  Keiji NOGAMI ,  Kenichi OGIWARA ,  Naruto SHIMONISHI

IPC: G01N33/86 ,  G01N33/49

Abstract: Provided is a method by which a titer of a coagulation factor inhibitor can be measured simply and in a short time. The present invention relates to a method for measuring a titer of a coagulation factor inhibitor. The method includes: preparing a mixed specimen containing a subject blood specimen and a normal blood specimen; heating the mixed specimen and acquiring a coagulation reaction curve for the heated mixed specimen; acquiring a coagulation reaction curve for the mixed specimen that has not been heated; calculating a parameter related to the coagulation reaction curve of the mixed specimen that has not been heated as a first parameter; calculating a parameter related to the coagulation reaction curve of the heated mixed specimen as a second parameter; and calculating a titer of a coagulation factor inhibitor in the subject blood specimen on the basis of the ratio or the difference between the first parameter and the second parameter.

公开(公告)号：US20210223270A1

公开(公告)日：2021-07-22

申请号：US17263697

申请日：2019-11-05

Applicant: Public University Corporation Nara Medical University ,  For You Medical Corporation ,  TOMO CO., LTD.

Inventor： Kazumasa TORIMOTO ,  Kiyohide FUJIMOTO ,  Tomohiro UEDA

IPC: G01N33/92 ,  G01N30/72

Abstract: A method for diagnosing interstitial cystitis includes measuring at least any one kind of lysophosphatidylcholine. A system and program for diagnosing a possibility of interstitial cystitis or bladder pain syndrome is also provided.

公开(公告)号：US20180045709A1

公开(公告)日：2018-02-15

申请号：US15791551

申请日：2017-10-24

Applicant: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY ,  CHUGAI SEIYAKU KABUSHIKI KAISHA ,  SYSMEX CORPORATION

Inventor： Midori SHIMA ,  Keiji NOGAMI ,  Tomoko MATSUMOTO ,  Takehisa KITAZAWA ,  Tetsuhiro SOEDA ,  Yuka IKEDA

IPC: G01N33/49 ,  G01N33/86 ,  C12Q1/56 ,  G01N21/59

CPC classification number: G01N33/4905 ,  B01L3/00 ,  C12Q1/56 ,  G01N21/51 ,  G01N21/59 ,  G01N33/86 ,  G01N2201/122

Abstract: The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor VIII-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and an apparatus for blood coagulation analysis. Furthermore, the present invention relates to an apparatus and computer program for evaluating coagulability of a blood specimen.

公开(公告)号：US20170315142A1

公开(公告)日：2017-11-02

申请号：US15498746

申请日：2017-04-27

Applicant: SYSMEX CORPORATION ,  PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY

Inventor： Midori SHIMA ,  Keiji NOGAMI ,  Tomoko MATSUMOTO ,  Sho SHINOHARA ,  Nobuo ARAI

IPC: G01N33/86

CPC classification number: G01N33/86 ,  G01N21/272 ,  G01N21/82 ,  G01N33/4905

Abstract: Disclosed is a method for analyzing a blood specimen, including the steps of: coagulating a blood specimen in the presence of an activating agent for fibrinolytic system to acquire a coagulation waveform; and acquiring information about fibrinolytic capacity of the blood specimen based on the acquired coagulation waveform.

公开(公告)号：US20150290163A1

公开(公告)日：2015-10-15

申请号：US14439124

申请日：2013-11-01

Applicant: COSMED PHARMACEUTICAL CO., LTD. ,  OSAKA UNIVERSITY ,  PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY

Inventor： Ying-shu Quan ,  Fumio Kamiyama ,  Mio Saito ,  Shinsaku Nakagawa ,  Naoki Okada ,  Sachiko Hirobe ,  Hideo Asada

IPC: A61K31/203

CPC classification number: A61K31/203 ,  A61K9/0021 ,  A61K31/122 ,  A61K31/375 ,  A61M37/00 ,  A61M2037/0046 ,  A61K2300/00

Abstract: An object to be achieved by the present invention is to provide a microneedle array which is able to supply effectively retinoic acid to the skin and effective in treating pimples, stains or wrinkles.The retinoic acid microneedle array comprises: a microneedle array having a microneedle substrate 5 and microneedles 1 disposed on the microneedle substrate 5; and a drug retained on the microneedles 1 and containing a water-swelling polymer and retinoic acid.

Abstract translation: 本发明要实现的目的是提供一种能够有效地向皮肤供应视黄酸并有效治疗粉刺，污渍或皱纹的微针阵列。 视黄酸微针阵列包括：微针阵列，其具有设置在微针基底5上的微针基底5和微针1; 和保留在微针1上并含有水溶胀性聚合物和视黄酸的药物。

公开(公告)号：US12022590B2

公开(公告)日：2024-06-25

申请号：US17798650

申请日：2021-02-19

Applicant: KYOCERA Corporation ,  Public University Corporation Nara Medical University

Inventor： Katsuhiro Mitsui ,  Hidetaka Katou ,  Kenji Obayashi

IPC: H05B47/16

CPC classification number: H05B47/16

Abstract: An illumination device includes a light emitter configured to emit illumination light and a controller configured to control the light emitter. The controller controls the illumination light such that a first decrease ratio of melanopic illuminance of illumination light during night-time illumination to melanopic illuminance of illumination light during daytime illumination is higher than a second decrease ratio of illuminance of the illumination light during the night-time illumination to illuminance of the illumination light during the daytime illumination.

公开(公告)号：US20230156892A1

公开(公告)日：2023-05-18

申请号：US17798650

申请日：2021-02-19

Applicant: KYOCERA Corporation ,  Public University Corporation Nara Medical University

Inventor： Katsuhiro MITSUI ,  Hidetaka KATOU ,  Kenji OBAYASHI

IPC: H05B47/16

CPC classification number: H05B47/16

Abstract: An illumination device includes a light emitter configured to emit illumination light and a controller configured to control the light emitter. The controller controls the illumination light such that a first decrease ratio of melanopic illuminance of illumination light during night-time illumination to melanopic illuminance of illumination light during daytime illumination is higher than a second decrease ratio of illuminance of the illumination light during the night-time illumination to illuminance of the illumination light during the daytime illumination.

公开(公告)号：US20220373565A1

公开(公告)日：2022-11-24

申请号：US17620436

申请日：2020-06-19

Applicant: SEKISUI MEDICAL CO., LTD. ,  PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY

Inventor： Toshiki KAWABE ,  Yukio ODA ,  Midori SHIMA ,  Keiji NOGAMI ,  Kenichi OGIWARA ,  Naruto SHIMONISHI

IPC: G01N33/86 ,  G16H10/40

Abstract: An APTT prolongation factor estimation system includes one or more facilities each including an analyzer which measures a blood coagulation reaction of a subject blood specimen, a database which stores data on a blood coagulation reaction and APTT prolongation factor of blood specimens, and a computer which estimates an APTT prolongation factor of the subject blood specimen based on the data on the blood coagulation reaction from the analyzer and the data stored in the database. The facilities each further includes a data transmission unit which transmits, to the computer, the data on the blood coagulation reaction of the subject blood specimen obtained by the analyzer, and a data reception unit which receives a result of the estimation of the APTT prolongation factor, which is obtained by the computer, regarding the subject blood specimen measured by each of the analyzers.